{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:09:01Z","timestamp":1794589741064,"version":"4.9.1"},"reference-count":100,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Background: Vascular calcification (VC) affects up to 90% of patients with end-stage renal disease and increases cardiovascular mortality 3- to 5-fold. Once considered passive mineral deposition, VC is now recognized as an active, toxin-driven process orchestrating vascular smooth muscle cell transdifferentiation, endothelial dysfunction, and matrix remodeling. However, current uremic toxin classifications remain biochemically oriented, providing limited clinical guidance for risk stratification and therapeutic selection. Methods: This comprehensive review reframes uremic toxin-driven VC through an integrated phenotypic lens, synthesizing molecular mechanisms, clinical biomarkers, and therapeutic targets into a unified translational framework. Results: We propose five mechanistic-clinical phenotypes representing distinct biological trajectories of vascular injury. These include (1) inflammatory-oxidative (dominated by indoxyl sulfate, p-cresyl sulfate, NLRP3 inflammasome activation), (2) mineral-metabolic (hyperphosphatemia, FGF23 excess, Klotho deficiency), (3) epigenetic-senescent (histone modifications, microRNA dysregulation, cellular senescence), (4) endocrine cross-talk (vitamin D, PTH, gut-derived metabolites), and (5) integrated toxic continuum (convergence of multiple pathways in advanced disease). A comprehensive biomarker panel spanning inflammatory markers, mineral metabolism parameters, epigenetic indicators, and endocrine-gut metabolites enables phenotypic stratification and therapeutic monitoring. Emerging therapies\u2014including tissue-nonspecific alkaline phosphatase inhibition, ectonucleotide pyrophosphatase\/phosphodiesterase 1 enzyme replacement, vitamin K2 activation, senolytic agents, and SNF472 crystal-growth blockade\u2014are mapped to their optimal phenotypic contexts. Conclusions: This phenotype-oriented paradigm transforms VC from an inevitable complication into a targetable and potentially reversible manifestation of uremic toxicity, establishing a translational foundation for precision-based vascular medicine in chronic kidney disease. The framework enables biomarker-guided patient stratification, rational therapeutic selection, and phenotype-enriched clinical trial design.<\/jats:p>","DOI":"10.3390\/toxins18020112","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:58:21Z","timestamp":1771837101000},"page":"112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Uremic Toxin-Driven Vascular Calcification in Chronic Kidney Disease: Molecular Pathways and Integrated Phenotypes"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5456-6785","authenticated-orcid":false,"given":"Rodolfo Fernando","family":"Rivera","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Pio XI Hospital ASST-Brianza, 20832 Desio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-0818","authenticated-orcid":false,"given":"Maria Teresa","family":"Sciarrone Alibrandi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9536-9254","authenticated-orcid":false,"given":"Nadia Edvige","family":"Foligno","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-1332","authenticated-orcid":false,"given":"Lorenza","family":"Magagnoli","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis, Department of Health Sciences, University of Milan, 20142 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis, Department of Health Sciences, University of Milan, 20142 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis, Department of Health Sciences, University of Milan, 20142 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.kint.2016.09.024","article-title":"Vascular calcification in chronic kidney disease: Different bricks in the wall?","volume":"91","author":"Vervloet","year":"2017","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00109-021-02037-7","article-title":"Vascular pathologies in chronic kidney disease: Pathophysiological mechanisms and novel therapeutic approaches","volume":"99","author":"Zietzer","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2215\/CJN.02120508","article-title":"Media calcification and intima calcification are distinct entities in chronic kidney disease","volume":"3","author":"Amann","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.suppl_5.97","article-title":"Arterial stiffening and vascular calcifications in end-stage renal disease","volume":"15","author":"London","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.100.21.2168","article-title":"Medial localization of mineralization-regulating proteins in association with M\u00f6nckeberg\u2019s sclerosis: Evidence for smooth muscle cell-mediated vascular calcification","volume":"100","author":"Shanahan","year":"1999","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and Monckeberg\u2019s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.ackd.2019.10.004","article-title":"Valvular Calcification in Chronic Kidney Disease","volume":"26","author":"Brandenburg","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_9","first-page":"1195","article-title":"Chronic Kidney Disease and the Pathophysiology of Valvular Heart Disease","volume":"35","author":"Ternacle","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cozzolino, M., Magagnoli, L., and Ciceri, P. (2025). From Physicochemical Classification to Multidimensional Insights: A Comprehensive Review of Uremic Toxin Research. Toxins, 17.","DOI":"10.3390\/toxins17060295"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cozzolino, M., Ciceri, P., Galassi, A., Mangano, M., Carugo, S., Capelli, I., and Cianciolo, G. (2019). The Key Role of Phosphate on Vascular Calcification. Toxins, 11.","DOI":"10.3390\/toxins11040213"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lin, C.-J., Wu, V., Wu, P.-C., and Wu, C.-J. (2015). Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132589"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Molinaro, M., Cozzolino, M., and Ciceri, P. (2025). Kynurenine Promotes Phosphate-Induced Endothelial Calcification via Endothelial-to-Mesenchymal Transition, Osteoblastic Differentiation and AhR Activation. Toxins, 17.","DOI":"10.3390\/toxins17080421"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3892\/etm.2024.12708","article-title":"The role and mechanism of protein post-translational modification in vascular calcification (Review)","volume":"28","author":"Wang","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Falconi, C.A., da Cruz Junho, C.V., Foga\u00e7a-Ruiz, F., Vernier, I.C.S., da Cunha, R.S., Stinghen, A.E.M., and Carneiro-Ramos, M.S. (2021). Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.686249"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rapp, N., Evenepoel, P., Stenvinkel, P., and Schurgers, L. (2020). Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees. Toxins, 12.","DOI":"10.3390\/toxins12100624"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: Classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2215\/CJN.02660221","article-title":"Classification of Uremic Toxins and Their Role in Kidney Failure","volume":"16","author":"Rosner","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000528040","article-title":"Proposal for a New Classification of Solutes of Interest in Uremia and Hemodialysis","volume":"52","author":"Kashani","year":"2023","journal-title":"Blood Purif."},{"key":"ref_20","unstructured":"Popay, J., Roberts, H., Sowden, A., Petticrew, M., Arai, L., Rodgers, M., Britten, N., Roen, K., and Duffy, S. (2006). Guidance on the Conduct of Narrative Synthesis in Systematic Reviews: A Product from the ESRC Methods Programme, Lancaster University."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lim, Y.J., Sidor, N.A., Tonial, N.C., Che, A., and Urquhart, B.L. (2021). Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. Toxins, 13.","DOI":"10.3390\/toxins13020142"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_23","first-page":"307","article-title":"Uremic Toxins and Cardiovascular System","volume":"39","author":"Valkenburg","year":"2021","journal-title":"Cardiol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Holmar, J., de la Puente-Secades, S., Floege, J., Noels, H., Jankowski, J., and Orth-Alampour, S. (2020). Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review. Cells, 9.","DOI":"10.3390\/cells9112428"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ekir.2020.09.032","article-title":"Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis\u2014Subgroup Analyses of the CALIPSO Trial","volume":"5","author":"Raggi","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chao, C.-T., and Lin, S.-H. (2021). Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126270"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10522-025-10279-y","article-title":"Mechanisms of endothelial senescence and vascular aging","volume":"26","author":"Li","year":"2025","journal-title":"Biogerontology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1002\/jcp.30891","article-title":"Mitochondria and vascular calcification in chronic kidney disease: Lessons learned from the past to improve future therapy","volume":"237","author":"Pongsuwan","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14779072.2023.2174525","article-title":"The pathophysiology and management of vascular calcification in chronic kidney disease patients","volume":"21","author":"Kanbay","year":"2023","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2016.11.012","article-title":"Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho","volume":"100","author":"Yamada","year":"2017","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Evenepoel, P., Dejongh, S., Verbeke, K., and Meijers, B. (2020). The Role of Gut Dysbiosis in the Bone-Vascular Axis in Chronic Kidney Disease. Toxins, 12.","DOI":"10.3390\/toxins12050285"},{"key":"ref_34","first-page":"20","article-title":"Clinical management of anemia in patients with CKD","volume":"34","author":"Rivera","year":"2017","journal-title":"G. Ital. Nefrol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Khodadadiyan, A., Rahmanian, M., Shekouh, D., Golmohammadi, M., Ghaedi, A., Bazrgar, A., Sayadi, M., Bazrafshan, M., Heydari, A., and Bazrafshan Drissi, H. (2023). Evaluating the effect of vitamin D supplementation on serum levels of 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, parathyroid hormone and renin-angiotensin-aldosterone system: A systematic review and meta-analysis of clinical trials. BMC Nutr., 9.","DOI":"10.1186\/s40795-023-00786-x"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1007\/s12011-021-02598-1","article-title":"The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: A Systematic Review and Time-Response Meta-Analysis","volume":"199","author":"Magzoub","year":"2021","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1002\/mco2.200","article-title":"Vascular calcification: Molecular mechanisms and therapeutic interventions","volume":"4","author":"Pan","year":"2023","journal-title":"MedComm"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Siracusa, C., Carabetta, N., Morano, M.B., Manica, M., Strangio, A., Sabatino, J., Leo, I., Castagna, A., Cianflone, E., and Torella, D. (2024). Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252313096"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marreiros, C., Viegas, C., and Simes, D. (2022). Targeting a Silent Disease: Vascular Calcification in Chronic Kidney Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232416114"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2023.2266381","article-title":"Future treatment of vascular calcification in chronic kidney disease","volume":"24","author":"Cozzolino","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacbts.2020.02.002","article-title":"Targeting Vascular Calcification in Chronic Kidney Disease","volume":"5","author":"Nelson","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"B\u00e4ck, M., Aranyi, T., Cancela, M.L., Carracedo, M., Concei\u00e7\u00e3o, N., Leftheriotis, G., Macrae, V., Martin, L., Nitschke, Y., and Pasch, A. (2018). Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement from the COST Action EuroSoftCalcNet. Front. Cardiovasc. Med., 5.","DOI":"10.3389\/fcvm.2018.00196"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jcb.22607","article-title":"Runx2\/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis","volume":"110","author":"Speer","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/15384101.2022.2064957","article-title":"A long non-coding RNA H19\/microRNA-138\/TLR3 network is involved in high phosphorus-mediated vascular calcification and chronic kidney disease","volume":"21","author":"Liu","year":"2022","journal-title":"Cell Cycle"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1681\/ASN.2008070692","article-title":"Vascular calcification: The killer of patients with chronic kidney disease","volume":"20","author":"Mizobuchi","year":"2009","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/ATVBAHA.123.319308","article-title":"Upregulated LncRNA H19 Sponges MiR-106a-5p and Contributes to Aldosterone-Induced Vascular Calcification via Activating the Runx2-Dependent Pathway","volume":"43","author":"Li","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Huang, Y., Zhan, W., Song, C., Tan, M., Wu, L., and Wu, S. (2025). The lncRNA SENCR knockdown alleviates vascular calcification via miR-4731-5p by suppressing endoplasmic reticulum stress. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0323058"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MNH.0000000000000797","article-title":"Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: Homeostatic interactions and emerging therapeutics","volume":"31","author":"Agoro","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, K., Husson, H., and Sabbagh, Y. (2025). Therapeutic approaches for the treatment of genetic and acquired cardiovascular calcification. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1636432"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1681\/ASN.2016121350","article-title":"C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients","volume":"28","author":"Eisenga","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","article-title":"Macrophages in cardiovascular diseases: Molecular mechanisms and therapeutic targets","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, C., Liang, Q., He, S., Zhu, J., Lin, X., Lin, G., Wu, D., Zhang, W., and Wang, Z. (2023). Role of inflammation and immunity in vascular calcification: A bibliometric and visual analysis, 2000\u20132022. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1258230"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/ATVBAHA.117.309182","article-title":"Magnesium Counteracts Vascular Calcification: Passive Interference or Active Modulation?","volume":"37","author":"Shanahan","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, L., Yao, J., Yao, Y., and Bostr\u00f6m, K.I. (2021). Contributions of the Endothelium to Vascular Calcification. Front. Cell. Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.620882"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rao, Z., Zheng, Y., Xu, L., Wang, Z., Zhou, Y., Chen, M., Dong, N., Cai, Z., and Li, F. (2022). Endoplasmic Reticulum Stress and Pathogenesis of Vascular Calcification. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.918056"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00774-019-01076-y","article-title":"The protective effects of long non-coding RNA-ANCR on arterial calcification","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2016.09.071","article-title":"Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis","volume":"254","author":"Ciceri","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Lu, Y., Yuan, T., Min, X., Yuan, Z., and Cai, Z. (2021). AMPK: Potential Therapeutic Target for Vascular Calcification. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.670222"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00210-023-02627-x","article-title":"AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats","volume":"397","author":"Hewedy","year":"2024","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ciceri, P., Falleni, M., Tosi, D., Martinelli, C., Cannizzo, S., Marchetti, G., D\u2019Arminio Monforte, A., Bulfamante, G., Block, G.A., and Messa, P. (2019). Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235925"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbrc.2022.03.051","article-title":"IL-17A promotes vascular calcification in an ex vivo murine aorta culture","volume":"604","author":"Mukai","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Roumeliotis, S., Duni, A., Vaios, V., Kitsos, A., Liakopoulos, V., and Dounousi, E. (2022). Vitamin K Supplementation for Prevention of Vascular Calcification in Chronic Kidney Disease Patients: Are We There Yet?. Nutrients, 14.","DOI":"10.3390\/nu14050925"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Li, T., Wang, Y., and Tu, W.-p. (2023). Vitamin K supplementation and vascular calcification: A systematic review and meta-analysis of randomized controlled trials. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1115069"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Neofytou, I.E., Stamou, A., Demopoulos, A., Roumeliotis, S., Zebekakis, P., Liakopoulos, V., Stamellou, E., and Dounousi, E. (2024). Vitamin K for Vascular Calcification in Kidney Patients: Still Alive and Kicking, but Still a Lot to Learn. Nutrients, 16.","DOI":"10.3390\/nu16121798"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Izzo, C., Secondulfo, C., Bilancio, G., Visco, V., Virtuoso, N., Migliarino, S., Ciccarelli, M., Di Pietro, P., La Mura, L., and Damato, A. (2024). Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview. Life, 14.","DOI":"10.3390\/life14030418"},{"key":"ref_68","first-page":"2","article-title":"Inhibition of alkaline phosphatase impairs dyslipidemia and protects mice from atherosclerosis","volume":"251","author":"Bessueille","year":"2023","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cvr\/cvaa299","article-title":"TNAP as a therapeutic target for cardiovascular calcification: A discussion of its pleiotropic functions in the body","volume":"118","author":"Goettsch","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"ziaf065","DOI":"10.1093\/jbmrpl\/ziaf065","article-title":"Recombinant ectonucleotide pyrophosphatase\/phosphodiesterase 1 (ENPP1) decreases vascular calcification and prevents osteomalacia in a rat model of chronic kidney disease","volume":"9","author":"Laurion","year":"2025","journal-title":"JBMR Plus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/jbmr.4315","article-title":"INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice","volume":"36","author":"Cheng","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","article-title":"The Klotho proteins in health and disease","volume":"15","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"115693","DOI":"10.1016\/j.biopha.2023.115693","article-title":"Dietary antioxidants and vascular calcification: From pharmacological mechanisms to challenges","volume":"168","author":"Lian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"107261","DOI":"10.1016\/j.phrs.2024.107261","article-title":"Sirtuin 3 in renal diseases and aging: From mechanisms to potential therapies","volume":"206","author":"Peng","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing Progression of Cardiovascular Calcification with SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/ckj\/sfz144","article-title":"Trial design and baseline characteristics of CaLIPSO: A randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification","volume":"14","author":"Bellasi","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ckj\/sfab117","article-title":"The CALCIPHYX study: A randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis","volume":"15","author":"Sinha","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMoa2304820","article-title":"Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure","volume":"389","author":"Blankestijn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2014010042","article-title":"Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD","volume":"26","author":"Schulman","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: A randomized study","volume":"7","author":"Bellasi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of Treating Hyperphosphatemia with Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients with Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"The EVOLVE Trial Investigators (2012). Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N. Engl. J. Med., 367, 2482\u20132494.","DOI":"10.1056\/NEJMoa1205624"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2011.10.041","article-title":"Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial","volume":"59","author":"Westenfeld","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: The Valkyrie Study","volume":"31","author":"Pyfferoen","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.jrn.2024.09.005","article-title":"Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients with Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial","volume":"35","author":"Headley","year":"2025","journal-title":"J. Ren. Nutr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s40620-022-01283-3","article-title":"High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: A post-hoc analysis from the HDFit randomized controlled trial","volume":"35","author":"Lima","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.02.005","article-title":"Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study","volume":"98","author":"Lewerin","year":"2017","journal-title":"Bone"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/HJH.0000000000004046","article-title":"Connecting the dots: Renin-angiotensin-aldosterone system, vitamin D, and hypertension","volume":"43","author":"Loh","year":"2025","journal-title":"J. Hypertens."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"196","DOI":"10.33393\/gcnd.2017.674","article-title":"The Cardiorenal Anemia Syndrome. Part One: Epidemiology and Clinical Aspects","volume":"29","author":"Rivera","year":"2017","journal-title":"G. Tec. Nefrol. Dial."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.33393\/gcnd.2018.574","article-title":"La sindrome anemica-cardio-renale. Seconda parte: Diagnostica","volume":"30","author":"Rivera","year":"2018","journal-title":"G. Tec. Nefrol. Dial."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.33393\/gcnd.2018.589","article-title":"La sindrome anemica cardio-renale. Terza parte: Terapia","volume":"30","author":"Rivera","year":"2018","journal-title":"G. Tec. Nefrol. Dial."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"(2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease\u2013mineral and bone disorder: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/2\/112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:17:54Z","timestamp":1772083074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/2\/112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["toxins18020112"],"URL":"https:\/\/doi.org\/10.3390\/toxins18020112","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]}}}